|
Diabetes Mellitus Interagency Coordinating Committee (DMICC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, IHS, OS
|
NIDDK, CSR, NCATS, NCCAM, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM
|
The DMICC facilitates cooperation, communication, and collaboration on diabetes among these government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other’s expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate.
|
|
Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS)
|
Research Initiative
|
CDC, IHS
|
NIDDK, NCATS, NCI, NCMHD, NEI, NHLBI, NIA, NICHD
|
The Diabetes Prevention Program (DPP) showed that lifestyle change or metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP.
|
|
Diabetic Retinopathy Clinical Research Network
|
Research Initiative
|
OS
|
NEI, NIDDK
|
The Diabetic Retinopathy Clinical Research Network (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the NEI, and co-funded by OS, through NIDDK, with the Special Funding Program for Type 1 Diabetes Research.
|
|
Diagnosis, Treatment, and Medical Service Utilization in Medicare and Medicaid Population
|
Research Initiative
|
CMS
|
CC
|
CMS and NIH CC Rehabilitation Medicine (RMD) agreed to collaborate in data-sharing for research the results of which may be helpful to improve medical-service quality, utilization, and effectiveness for Medicare and Medicaid beneficiaries. CMS will provide electronic data to NIH CC/RMD who will perform analyses that are agreed to by both parties.
|
|
Diet-Induced Hypomethylation in Preneoplastic Liver
|
Research Initiative
|
FDA
|
NCI
|
The Food and Drug Administration (FDA) National Center for Toxicological Research and the National Cancer Institute (NCI) Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that predetermine individual susceptibility to development of hepatocellular carcinoma and to provide evidence that epigenetic alterations may be used as markers of susceptibility to disease development and correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies.
|
|
Dietary Supplements Ingredient Database (DSID)
|
Research Initiative
|
CDC, FDA
|
OD/DPCPSI/ODP, NCI, NHLBI, NIDDK
|
This U.S. Department of Agriculture (USDA) based program provides basic information about the nutrient content of selected ingredients in dietary supplements, compared to label-reported ingredient levels. The database provides statistical estimates—based on chemical analysis—of the nutrient content of selected ingredients in dietary supplements, compared with label-reported ingredient levels. Currently the Dietary Supplements Ingredient Database (DSID) provides estimated levels of 18 vitamin and mineral ingredients derived from analytical data for 115 representative unspecified adult multivitamin/multimineral supplements (MVMs). Additional dietary supplement ingredients will be included in future releases of the database.
|
|
Digital Quantitation of Plasma Cells in Marrow Biopsies
|
Research Initiative
|
FDA
|
CC
|
Collaboration with M Choi, WC Cheng, and A Badano from the Imaging Physics Lab, Division of Imaging and Applied Mathematics Office of Science and Engineering Labs, Center for Devices and Radiological Health, of the Food and Drug Administration (FDA). The project consists of developing software and establish validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis and therapy monitoring of marrow disorders. Last winter (Jan-March 2014) we had the fortune to have an engineering student with us who had previous experience developing image analysis software and volunteered to help us moving our project forward. His final product is a working prototype that produces excellent results counting plasma cells in the bone marrow, and we are currently writing a paper for publication presenting the data.
|
|
Disaster Research Response Project
|
Research Initiative
|
ATSDR, CDC, FDA, OS
|
NIEHS, NLM, OD/DPCPSI
|
The NIH Disaster Research Response (DR2) Project is a pilot project aimed at creating an environmental health disaster research system through platforms of ready-to-go research data collection tools and a network of specially trained research responders. This project was developed and will be administered by the NIEHS and NLM. Elements of the system include epidemiologic questionnaires and clinical protocols, specially trained disaster researchers, environmental health disaster research networks, a reach-back roster of subject matter experts, and a support infrastructure that can be activated and deployed during public health emergencies and declared disasters. This effort will not only serve as a model for enhancing environmental health research responses, but will also provide invaluable lessons and platforms for others interested in advancing timely post-disaster research activities.
|
|
Dominantly Inherited Alzheimer''s Network (DIAN): International Network for the Identification, Evaluation, and Follow up of Families with Early Onset of Dominantly Inherited Alzheimer''s Disease
|
Research Initiative
|
FDA
|
NIA
|
This collaboration aims to set up an international network consisting of a consortium of scientific investigators that will have the responsibility to identify, recruit, evaluate, and follow-up individuals from families with early onset dominantly inherited Alzheimer’s Disease [i.e., families with the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) mutations or duplications or others still to be discovered].
|
|
Drug Induced Liver Injury Network (DILIN)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDDK
|
Both a prospective and retrospective database containing cases of drug-induced liver disease, the Drug Induced Liver Injury Network (DILIN) is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. One of the goals of the DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. The DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Three employees of FDA serve as ad hoc members on the committee overseeing the network activities.
|